Scientists have spent years studying how GLP-1 drugs affect inflammation, metabolism and blood vessels in the brain. (BSIP / Universal Images Group via Getty Images) Novo Nordisk says it still thinks ...

Add Yahoo as a preferred source to see more of our stories on Google. Brain CT scans of Alzheimer's disease. Endocrinologist Daniel Drucker says that the trials were well-done but the results are “a ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that revolutionized diabetes and weight loss did not slow the disease’s ...

CHICAGO (Reuters) -Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still ...

Shares of Novo Nordisk A/S took a dive in early Monday trading after the drugmaker said oral semaglutide, which is the key ingredient in the company’s Ozempic and Wegovy diabetes and weight-loss drugs ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

About 20 years ago, the U.S. Food and Drug Administration approved the first GLP-1 medication for Type 2 diabetes. Today, the landscape has shifted, as the agency has approved various ...

Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two major trials last month that found an older drug similar to Ozempic had no effect in slowing ...